Related Experiment Videos
Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma
Abstract:
Thirty-one patients with disseminated malignant melanoma received intramuscular recombinant leukocyte A interferon (rIFN-alpha A), 50 X 10(6) units/m2 three times weekly for a planned treatment duration of 3 months. Seven objective regressions (23%), which ranged in duration from 3 to 11.2+ months, were observed. Forty-two percent of 12 patients who were fully active (Eastern Cooperative Oncology Group [ECOG] performance score, 0) responded compared to 11% of 19 patients with impairment of performance status (ECOG, 1-3). Prior chemotherapy did not influence response rate. For all patients the median time to progression and of survival was 2 months and 6 months, respectively. Four patients had partial regressions in soft tissue (3, 4.6 months), pulmonary (7 months), and prostatic lesions (3 months). The latter was biopsy-proven and assessed by serial computerized tomography (CT) scans. Three had complete regressions of soft tissue disease (2 patients, 6.4 and 10+ months each), and liver involvement (11.2+ months). The major toxicities were moderate to severe fatigue (87%), anorexia (58%), and confusion (23%). Performance score deteriorated in 84% of patients during the time they were receiving rIFN-alpha A. Among the 13 patients whose tumors did not progress for at least 12 weeks, 7 required dose reductions or termination of treatment due to toxicities. Hematologic and hepatic toxicity was transient and of little clinical significance. The study indicates that rIFN-alpha A has some antitumor activity accompanied by difficult side effects in patients with disseminated malignant melanoma.
Insights
Recombinant leukocyte A interferon (rIFN-alpha A) showed antitumor activity in disseminated melanoma patients, with 23% objective regressions. However, significant toxicities like fatigue and confusion limited treatment for many.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Disseminated malignant melanoma presents a significant therapeutic challenge.
- Interferon-alpha has been explored for its potential in treating advanced cancers.
Purpose of the Study:
- To evaluate the efficacy and toxicity of intramuscular recombinant leukocyte A interferon (rIFN-alpha A) in patients with disseminated malignant melanoma.
Main Methods:
- Thirty-one patients received rIFN-alpha A (50 x 10^6 units/m2) intramuscularly three times weekly for 3 months.
- Objective regressions, duration of response, time to progression, and survival were assessed.
- Patient performance status (ECOG) and treatment-related toxicities were monitored.
Main Results:
- Seven objective regressions (23%) were observed, with durations ranging from 3 to 11.2+ months.
- Response rates were higher in patients with better performance status (42% vs. 11%).
- Major toxicities included fatigue (87%), anorexia (58%), and confusion (23%), leading to dose modifications in 54% of patients with stable disease.
Conclusions:
- rIFN-alpha A demonstrates some antitumor activity in disseminated malignant melanoma.
- Significant toxicities, including fatigue and confusion, frequently occurred and impacted treatment delivery.
- Further research may be needed to optimize interferon-based therapies or identify patient subsets who benefit most.